title: [Follicular variant of peripheral T-cell lymphoma: a clinicopathologic and genetic study of 2 cases].
abstract: OBJECTIVE
  To observe the clinicopathologic and genetic features of follicular variant of peripheral T-cell lymphoma (FV-PTCL), with particular attention to the relationship of this type of lymphoma with angioimmunoblastic T-cell lymphoma (AITL).
  
  
  METHODS
  The clinical data, hematoxylin and eosin-stained sections of lymph node biopsies from 2 FV-PTCL cases were reviewed. Immunohistochemical phenotyping and detection of EBV-encoded RNAs (EBER) through in situ hybridization (ISH) were performed. The EnVision two-step method was used for all antibodies except CXCL13 (by using three-step streptavidin immunoperoxidase method). Analysis of clonality and ITK/SYK gene rearrangement was conducted using PCR and RT-PCR assays, respectively.
  
  
  RESULTS
  Clinically, the two patients presented with superficial lymphadenopathy similarly. Histologically, case 1 showed a follicular/nodular lymphoid proliferation without marked germinal centers. The neoplastic cells comprised mainly medium sized cells with abundant, sometimes clear cytoplasms. Similar histologic findings were seen in case 2 in addition to a concurrent component mimicking typical AITL noticed. Of both cases, the neoplastic cells showed positive reactivity to CD3, CD4, CD10, PD1, and CXCL13. Positive hybridization signals for EBER were only seen in case 2, and double stains demonstrated that those EBV-positive cells were mostly the reactive transformed B-cells. Monoclonal T-cell proliferation was proved by the rearranged TCR gene detection in both cases. Neither of the current cases expressed ITK/SYK fusion transcripts.
  
  
  CONCLUSIONS
  FV-PTCL shows the similar or overlapped morphological and immunophenotypic features to those of AITL, possibly suggesting the presence of a potential relationship between these two types of lymphomas.
authors.affiliation: Department of Pathology, Fudan University Shanghai Cancer Center/Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: He-qin
authors.initials: HQ
authors.lastname: Zhan
authors.forename: Xiong-zeng
authors.initials: XZ
authors.lastname: Zhu
authors.forename: Xiao-qiu
authors.initials: XQ
authors.lastname: Li
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Zhou
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D054382:Chemokine CXCL13 / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D043169:Endostatins / Q000627:therapeutic use; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D007633:Keratins / Q000378:metabolism; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D011241:Prednisone / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011994:Recombinant Proteins; D012074:Remission Induction; D000072377:Syk Kinase; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C110663:CXCL13 protein, human; D054382:Chemokine CXCL13; D043169:Endostatins; D047908:Intracellular Signaling Peptides and Proteins; D015514:Oncogene Proteins, Fusion; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011994:Recombinant Proteins; D014750:Vincristine; D007633:Keratins; D004317:Doxorubicin; D003520:Cyclophosphamide; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; C080813:emt protein-tyrosine kinase; C522911:endostar protein; D011241:Prednisone